Singapore markets close in 1 hour 11 minutes
  • Straits Times Index

    3,300.78
    +14.45 (+0.44%)
     
  • Nikkei

    27,819.33
    -180.63 (-0.65%)
     
  • Hang Seng

    20,039.52
    +428.68 (+2.19%)
     
  • FTSE 100

    7,503.64
    -3.47 (-0.05%)
     
  • BTC-USD

    24,495.28
    +1,495.98 (+6.50%)
     
  • CMC Crypto 200

    576.14
    +44.92 (+8.46%)
     
  • S&P 500

    4,210.24
    +87.77 (+2.13%)
     
  • Dow

    33,309.51
    +535.11 (+1.63%)
     
  • Nasdaq

    12,854.80
    +360.88 (+2.89%)
     
  • Gold

    1,802.70
    -11.00 (-0.61%)
     
  • Crude Oil

    91.72
    -0.21 (-0.23%)
     
  • 10-Yr Bond

    2.7860
    0.0000 (0.00%)
     
  • FTSE Bursa Malaysia

    1,502.79
    +10.46 (+0.70%)
     
  • Jakarta Composite Index

    7,165.40
    +79.17 (+1.12%)
     
  • PSE Index

    6,680.68
    +208.84 (+3.23%)
     

Strength Seen in BioCryst (BCRX): Can Its 5.5% Jump Turn into More Strength?

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

BioCryst Pharmaceuticals (BCRX) shares ended the last trading session 5.5% higher at $9.62. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 1% gain over the past four weeks.

The rise in share prices may be attributable to positive investor expectations for BioCryst's BCX9250 following the FDA granting it Fast Track designation earlier this month.

This drugmaker is expected to post quarterly loss of $0.36 per share in its upcoming report, which represents a year-over-year change of -50%. Revenues are expected to be $63.92 million, up 28% from the year-ago quarter.

While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

For BioCryst, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on BCRX going forward to see if this recent jump can turn into more strength down the road.

The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

BioCryst is part of the Zacks Medical - Drugs industry. United Therapeutics (UTHR), another stock in the same industry, closed the last trading session 0.8% higher at $219.38. UTHR has returned 16.8% in the past month.

United Therapeutics' consensus EPS estimate for the upcoming report has changed +5.4% over the past month to $4.12. Compared to the company's year-ago EPS, this represents a change of +12.9%. United Therapeutics currently boasts a Zacks Rank of #3 (Hold).


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting